Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $275.00. The company’s shares closed yesterday at $164.89. According to TipRanks ...

The article provides an overview of recent developments in the healthcare sector, including Novo Nordisk's phase-out of ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

In the world of health, Novo Nordisk stops insulin pen production, Trump's potential health appointments draw attention, and ...

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...

Q3 2024 Earnings Call Transcript October 30, 2024 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $3.77. Operator: Good morning. My name is Cynthia, and I will be ...

In an unusual move, the U.S. Navy disclosed the location of Ohio-class submarine ... increase across multiple global fronts. The United States Navy's Ohio-class nuclear-powered ballistic missile ...

(RTTNews) - Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological ...